Median effect analysis of efficacy versus adverse effects of immunosuppressants.
about
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsImmunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolismAlterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors.FTY720: A new kid on the block for transplant immunosuppression.Clinical application of sirolimus in renal transplantation: an update.A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Sirolimus: its role in nephrology.Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.Tumor growth effects of rapamycin on human biliary tract cancer cells.An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine.Effect of sirolimus withdrawal in patients with deteriorating renal function.Janus kinase 3: a novel target for selective transplant immunosupression.Analysis of exposure-response relationship in everolimus-cyclosporine combination regimen.Relationship of cyclosporin and sirolimus blood concentrations regarding the incidence and severity of hyperlipidemia after kidney transplantation.
P2860
Q24246340-89C4EC3C-B6F2-4F9B-936A-C4FEFBEDECCFQ33738391-5BCFFBD9-A30D-4ED5-A5A2-9EC8C3927899Q35047701-11889AD0-476E-46AC-8E75-0D768E76E0D1Q35164822-652D274B-E06B-4F1E-8B10-1A61BE9BF8CAQ36054093-56100EC7-6389-438E-8536-9932D9A1A041Q36183858-08EDC352-CAB0-454D-AEC1-6DE72E42406DQ36341793-23300260-6A6C-419E-95C4-43EE1DDAC032Q37571930-D3576CEE-C1D6-489B-B0BA-BBD0B84B8F4EQ37873950-65111594-67AD-4307-8F7A-35CFCA74137EQ37924929-B50E1042-E1A0-4EBF-92EA-8291BBB68F2CQ39327387-E8C2DB32-70AA-49B3-AED8-3D2F707A930DQ44845684-97F079D1-E01B-4454-AD18-4B9EB137F8DFQ45034693-6DBCEBFF-8ECE-4519-B093-3E602EF9D670Q45058867-B2734280-8090-4477-AA76-D14AD72FABE6Q45177699-7D4DF23B-1D17-47A1-9621-F6BBE5FB341AQ46646008-A6F53469-AF72-4742-9AA0-2C4048B94211Q46885124-EF2C85D6-50FE-42A9-A7F0-0E5FF27FEBCA
P2860
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@ast
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@en
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@nl
type
label
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@ast
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@en
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@nl
prefLabel
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@ast
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@en
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@nl
P356
P1476
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
@en
P2093
P356
10.1067/MCP.2001.116309
P407
P577
2001-07-01T00:00:00Z